Description: Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Home Page: www.nuformix.com
60 Gracechurch Street
London,
EC3V 0HR
United Kingdom
Phone:
44 12 2362 7222
Officers
| Name | Title |
|---|---|
| Dr. Daniel John Gooding | Executive Director |
| Dr. Joanne M. Holland | Consultant |
| Mr. Benjamin Harber | Company Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1435 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 3 |